GR3004479T3 - - Google Patents

Info

Publication number
GR3004479T3
GR3004479T3 GR920400417T GR920400417T GR3004479T3 GR 3004479 T3 GR3004479 T3 GR 3004479T3 GR 920400417 T GR920400417 T GR 920400417T GR 920400417 T GR920400417 T GR 920400417T GR 3004479 T3 GR3004479 T3 GR 3004479T3
Authority
GR
Greece
Prior art keywords
solubilizer
stabilizers
humans
formulations
animals
Prior art date
Application number
GR920400417T
Other languages
English (en)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GR3004479T3 publication Critical patent/GR3004479T3/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
GR920400417T 1986-10-27 1992-05-04 GR3004479T3 (el)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US92338386A 1986-10-27 1986-10-27

Publications (1)

Publication Number Publication Date
GR3004479T3 true GR3004479T3 (el) 1993-03-31

Family

ID=25448603

Family Applications (1)

Application Number Title Priority Date Filing Date
GR920400417T GR3004479T3 (el) 1986-10-27 1992-05-04

Country Status (9)

Country Link
EP (1) EP0268110B1 (el)
JP (1) JPS63122628A (el)
AT (1) ATE74512T1 (el)
AU (1) AU614066B2 (el)
CA (1) CA1292686C (el)
DE (1) DE3778122D1 (el)
ES (1) ES2036558T3 (el)
GR (1) GR3004479T3 (el)
IE (1) IE60890B1 (el)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5037644A (en) * 1986-10-27 1991-08-06 Cetus Corporation Pharmaceutical compositions of recombinant interleukin-2 and formulation processes
US4931543A (en) * 1987-05-11 1990-06-05 Cetus Corporation Process for recovering microbially produced interleukin-2
US6060459A (en) * 1987-10-28 2000-05-09 Pro-Neuron, Inc. Enhancing blood cell count with oxypurine nucleosides
ES2054099T3 (es) * 1988-12-06 1994-08-01 Otsuka Pharma Co Ltd Composicion estabilizada de interleucina-1-g(b).
US6586222B1 (en) 1989-08-16 2003-07-01 Chiron Corporation Recombinant PR-3 and compositions thereof
US5998378A (en) * 1989-08-16 1999-12-07 Chiron Corporation Compositions for the inhibition of TNF hormone formation and uses thereof
US5843693A (en) * 1989-08-16 1998-12-01 Chiron Corporation Assay method for screening for inhibitors of proTNF conversion
JPH0791318B2 (ja) * 1989-09-21 1995-10-04 三井東圧化学株式会社 蛋白質水溶液、蛋白質水溶液の濃度増大方法および蛋白質製剤
US5830452A (en) * 1990-11-20 1998-11-03 Chiron Corporation Method for enhancing the anti-tumor therapeutic index of interleukin-2
US6063764A (en) * 1992-06-01 2000-05-16 Washington University & Chiron Corp. Method for using lipoprotein associated coagulation inhibitor to treat sepsis
US20030171292A1 (en) 1992-06-01 2003-09-11 Creasey Abla A. Method for using lipoprotein associated coagulation inhibitor to treat sepsis
KR100303872B1 (ko) * 1992-10-02 2001-11-22 크리스터 발스트룀, 프레드릭 베르그, 하랄트 알름 응고인자ⅷ제형을포함하는조성물,이것의제조방법및안정화제로서의계면활성제의사용방법
AU687763B2 (en) * 1992-10-20 1998-03-05 Central Laboratory Of The Netherlands Red Cross Blood Transfusion Service Interleukin-6 receptor antagonists
SE9301581D0 (sv) * 1993-05-07 1993-05-07 Kabi Pharmacia Ab Protein formulation
US6288030B1 (en) 1993-12-22 2001-09-11 Amgen Inc. Stem cell factor formulations and methods
KR20040040489A (ko) 2001-10-15 2004-05-12 카이론 코포레이션 조직 인자 경로 억제제（ｔｆｐｉ）의 저용량 투여에 의한패혈증의 치료
JP4810431B2 (ja) 2003-11-04 2011-11-09 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド Ｂ細胞に関連する癌に対する治療方法
EP2301575A1 (en) 2003-11-04 2011-03-30 Novartis Vaccines and Diagnostics, Inc. Methods of therapy for solid tumors expressing the CD40 cell-surface antigen
DE602004028270D1 (de) 2003-11-04 2010-09-02 Novartis Vaccines & Diagnostic Verwendung von antagonisten-anti-cd40-antikörpern zur behandlung von chronisch lymphozytischer leukämie
PT1682180E (pt) 2003-11-04 2010-02-10 Novartis Vaccines & Diagnostic Anticorpos monoclonais antagonistas anti-cd40 e métodos para a sua utilização
EP2243492A1 (en) 2003-11-04 2010-10-27 Novartis Vaccines and Diagnostics, Inc. Use of antagonist anti-cd40 monoclonal antibodies for treatment of multiple myeloma
GB0404586D0 (en) * 2004-03-01 2004-04-07 Britannia Pharmaceuticals Ltd Improvements in or relating to organic materials
KR100624013B1 (ko) 2004-06-25 2006-09-19 주식회사 녹십자홀딩스 동결건조된 알부민 비함유 재조합 사람 혈액응고 제 8인자 제제
JP5518608B2 (ja) * 2010-07-09 2014-06-11 ロート製薬株式会社 粘膜適用液状組成物
AR083847A1 (es) 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
WO2012075111A1 (en) 2010-11-30 2012-06-07 Novartis Ag Uses of anti-cd40 antibodies in combination therapy for b cell-related cancers
AU2011335551B2 (en) 2010-12-02 2016-10-06 Bionor Immuno As Peptide scaffold design
CA2821995C (en) 2011-01-06 2019-02-12 Bionor Immuno As Monomeric and multimeric peptides immunogenic against hiv
DE102012101864A1 (de) * 2012-03-06 2013-09-12 Gramme-Revit Gmbh Mittel zur Behandlung von Allergien und anderen Erkrankungen
WO2013182661A1 (en) 2012-06-06 2013-12-12 Bionor Immuno As Peptides derived from viral proteins for use as immunogens and dosage reactants
UA105278C2 (ru) 2012-09-06 2014-04-25 Інститут Біології Клітини Нан України Способ получения каталитически активных антител (абзимов) с сиалидазной активностью
CA3165974A1 (en) 2013-04-23 2014-10-30 Cedars-Sinai Medical Center Systems and methods for recording simultaneously visible light image and infrared light image from fluorophores
US10183078B2 (en) 2014-01-17 2019-01-22 Cedars-Sinai Medical Center Receptor targeting constructs and uses thereof
WO2015192078A1 (en) 2014-06-12 2015-12-17 Cedars-Sinai Medical Center Compositions and methods for treating cancers
US11786469B2 (en) 2014-07-22 2023-10-17 Cheolhee WON Silica nanoparticle composition for delivering bioactive material or protein such as a human proteasome
EP3215186A4 (en) 2014-11-04 2018-10-24 University of Southern California COMPOSITIONS AND METHODS FOR TREATING HIF-1alpha OVER-EXPRESSING CANCERS
US10441644B2 (en) 2015-05-05 2019-10-15 The Regents Of The University Of California H3.3 CTL peptides and uses thereof
ES2842849T3 (es) 2015-05-05 2021-07-15 Univ California Péptidos CTL H3.3 y usos de los mismos
EP3345000B1 (en) 2015-08-31 2022-08-31 Cedars-Sinai Medical Center Novel blood cell biomarker for late onset alzheimer's disease
WO2017138924A1 (en) 2016-02-09 2017-08-17 Autotelic Llc Compositions and methods for treating pancreatic cancer
KR101843985B1 (ko) 2016-02-09 2018-03-30 오토텔릭 엘엘씨 암을 치료하기 위한 조성물과 방법
WO2018143787A1 (ko) 2017-02-06 2018-08-09 주식회사 레모넥스 생리활성물질 전달체
MX2019009271A (es) 2017-02-06 2019-10-30 Lemonex Inc Portador de sustancia fisiologicamente activa.
EP3658139A4 (en) 2017-07-25 2021-04-07 Cedars-Sinai Medical Center METHODS OF TREATMENT OF HEPATIC DISEASES
KR102152348B1 (ko) 2017-09-05 2020-09-08 주식회사 레모넥스 세포 운명 조절용 조성물
WO2020097566A1 (en) 2018-11-08 2020-05-14 Cedars-Sinai Medical Center Use of clazakizumab to desensitize and improve renal transplantation in hla-sensitized patients
AU2019404553A1 (en) 2018-12-20 2021-06-24 Cedars-Sinai Medical Center Clazakizumab in the treatment of chronic antibody-mediated rejection of organ transplant
EP4103587A1 (en) 2020-02-14 2022-12-21 Immunor AS Corona virus vaccine
KR20230107598A (ko) * 2020-11-13 2023-07-17 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 인간 인터루킨 2 변이체 또는 이의 유도체를 포함하는 약학적 조성물 및 이의 용도

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2652636A1 (de) * 1976-11-19 1978-05-24 Hans Uwe Dr Rer Nat Wolf Verfahren zur stabilisierung von proteinen und verwandten verbindungen waehrend ihrer reinigung, isolierung und lagerung
US4457916A (en) * 1982-08-31 1984-07-03 Asahi Kasei Kogyo Kabushiki Kaisha Method for stabilizing Tumor Necrosis Factor and a stable aqueous solution or powder containing the same
EP0211835B1 (en) * 1984-03-28 1990-01-03 Cetus Corporation Pharmaceutical compositions of microbially produced interleukin-2
EP0158487B1 (en) * 1984-04-09 1991-08-28 Takeda Chemical Industries, Ltd. Stable composition of interleukin-2
CA1297003C (en) * 1985-09-20 1992-03-10 Jack H. Nunberg Composition and method for treating animals
US4822605A (en) * 1986-02-18 1989-04-18 Exovir, Inc. Compositions and methods employing the same for the treatment of viral and cancerous skin lesions and the like

Also Published As

Publication number Publication date
IE872844L (en) 1988-04-27
AU614066B2 (en) 1991-08-22
EP0268110B1 (en) 1992-04-08
IE60890B1 (en) 1994-08-24
DE3778122D1 (de) 1992-05-14
JPS63122628A (ja) 1988-05-26
AU8018187A (en) 1988-04-28
EP0268110A1 (en) 1988-05-25
ES2036558T3 (es) 1993-06-01
CA1292686C (en) 1991-12-03
ATE74512T1 (de) 1992-04-15

Similar Documents

Publication Publication Date Title
GR3004479T3 (el)
FI874706A (fi) Menetelmä glykosyloimattoman yhdistelmäinterferoni- :n stabiilien, farmaseuttisten koostumusten valmistamiseksi
AU590896B2 (en) Improved formulations for recombinant beta-interferon
DE3868886D1 (de) Fettsaeure-zusammensetzungen.
EP0693924A4 (en) METHODS OF ADMINISTRATION -i (IN VIVO) OF BIOLOGICAL SUBSTANCES AND COMPOSITIONS USED IN SUCH METHODS
DK0414263T3 (da) Fremgangsmåde til stabilisering af et fast farmaceutisk præparat indeholdende cycliske aminosyrer
IL99628A0 (en) Backbone cyclic peptides,processes for their preparation and pharmaceutical compositions containing them
IL68456A0 (en) Pharmaceutical compositions comprising perfluorohydrocarbons as vehicles
FI944535A0 (fi) Rapamysiinikoostumuksia oraalisesti annettaviksi
EP0321968A3 (en) Compounds active on the cardiovascular system
KR900700124A (ko) 흑색종 치료용 il-2 및 dtic의 치료 조성물
FR2707638B1 (fr) Nouveaux dérivés d'amino-acides, leurs procédés de préparation et leur application thérapeutique.
IL85992A0 (en) Dihydropyridinamides,their preparation and pharmaceutical compositions containing them
IL85189A (en) Beta-alkyl substituted melatonins,their preparation and pharmaceutical compositions containing them
FI863078A0 (fi) Kontinuerligt frigoerande peptidkompositioner.
GB8603964D0 (en) Compositions
ES8504774A1 (es) Procedimiento para preparar derivados de 2-piperacinil-quinazolina
ATE175213T1 (de) Ch0ndromodulin-ii protein
DE3781017D1 (de) Cytotoxische zusammensetzung aus "killer"-zellen.
IT8622051A1 (it) Composizioni farmaceutiche ad attivita' cicatrizzante
EP0321967A3 (en) Compounds active on the cardiovascular system
IT8921095A0 (it) Composizione per l'aumento del guadagno di peso.